Trastuzumab

About

Therapy type: Targeted therapy

Therapy strategy: HER2 inhibition

Mappings

NCI Thesaurus: Trastuzumab (ncit:C1647)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
EMA (1) FDA (1)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
FDA (1)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
EMA (4) FDA (2) HSE (3)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (4) HSE (1)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
EMA (1) FDA (4)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
EMA (1) FDA (2)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HSE (1)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HSE (1)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HSE (1)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HSE (1)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HSE (4)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (1) HSE (4)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
FDA (1)	HER2-positive	Gastrointestinal Stromal Tumor	Trastuzumab
EMA (1) FDA (1)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Trastuzumab, Tucatinib
EMA (3) HSE (2)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
EMA (3)	ERBB2 amplification	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
EMA (2) HSE (2)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
EMA (1)	HER2-positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
EMA (1) HSE (1)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab
EMA (1) HSE (1)	HER2-positive	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab
EMA (2)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab
EMA (2)	ERBB2 amplification	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
EMA (1)	ERBB2 amplification	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
EMA (1)	ERBB2 amplification	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab
EMA (1)	ERBB2 amplification	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab
EMA (1)	HER2-positive	Esophagogastric Adenocarcinoma	Capecitabine, Cisplatin, Trastuzumab
EMA (1)	HER2-positive	Esophagogastric Adenocarcinoma	Cisplatin, Fluorouracil, Trastuzumab
EMA (1)	ERBB2 amplification	Esophagogastric Adenocarcinoma	Capecitabine, Cisplatin, Trastuzumab
EMA (1)	ERBB2 amplification	Esophagogastric Adenocarcinoma	Cisplatin, Fluorouracil, Trastuzumab
EMA (1)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Carboplatin, Fluorouracil, Pembrolizumab, Trastuzumab
EMA (1)	ER positive, HER2-positive, PR negative	Invasive Breast Carcinoma	Lapatinib, Trastuzumab
EMA (1)	ER positive, ERBB2 amplification, PR negative	Invasive Breast Carcinoma	Lapatinib, Trastuzumab
HSE (2)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
HSE (2)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab
HSE (2)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab, Vinorelbine
HSE (2)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab
HSE (1)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
HSE (1)	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
HSE (1)	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
FDA (1)	HER2-positive, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Trastuzumab, Tucatinib